Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41591-020-01194-5 http://scihub22266oqcxt.onion/10.1038/s41591-020-01194-5 33335323!ä!33335323 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Med 2021 ; 27 (2): 270-278 Nephropedia Template TP {{tp|p=33335323|t=2021. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial |pdf=|usr=}}{{33335323}} gab.com Text T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial JO: Nat Med http://www.kidney.de/pget.php?&tw=1&pmid=33335323 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective vaccines are urgently needed(1). Strong, Th1-skewed T cell responses can drive protective humoral and cell-mediated immune responses(2) and might reduce the potential for disease enhancement(3). Cytotoxic T cells clear virus-infected host cells and contribute to control of infection(4). Studies of patients infected with SARS-CoV-2 have suggested a protective role for both humoral and cell-mediated immune responses in recovery from COVID-19 (refs. (5,6)). ChAdOx1 nCoV-19 (AZD1222) is a candidate SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein. We recently reported preliminary safety and immunogenicity data from a phase 1/2 trial of the ChAdOx1 nCoV-19 vaccine (NCT04400838)(7) given as either a one- or two-dose regimen. The vaccine was tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. Here we describe, in detail, exploratory analyses of the immune responses in adults, aged 18-55 years, up to 8 weeks after vaccination with a single dose of ChAdOx1 nCoV-19 in this trial, demonstrating an induction of a Th1-biased response characterized by interferon-gamma and tumor necrosis factor-alpha cytokine secretion by CD4(+) T cells and antibody production predominantly of IgG1 and IgG3 subclasses. CD8(+) T cells, of monofunctional, polyfunctional and cytotoxic phenotypes, were also induced. Taken together, these results suggest a favorable immune profile induced by ChAdOx1 nCoV-19 vaccine, supporting the progression of this vaccine candidate to ongoing phase 2/3 trials to assess vaccine efficacy. Twit Text FOAVip T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial ????Nat Med http://www.kidney.de/pget.php?&tw=1&pmid=33335323 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33335323 #FOAvip English Wikipedia <ref>{{Cite pmid|33335323}}</ref> T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial #MMPMID33335323 Ewer KJ; Barrett JR; Belij-Rammerstorfer S; Sharpe H; Makinson R; Morter R; Flaxman A; Wright D; Bellamy D; Bittaye M; Dold C; Provine NM; Aboagye J; Fowler J; Silk SE; Alderson J; Aley PK; Angus B; Berrie E; Bibi S; Cicconi P; Clutterbuck EA; Chelysheva I; Folegatti PM; Fuskova M; Green CM; Jenkin D; Kerridge S; Lawrie A; Minassian AM; Moore M; Mujadidi Y; Plested E; Poulton I; Ramasamy MN; Robinson H; Song R; Snape MD; Tarrant R; Voysey M; Watson MEE; Douglas AD; Hill AVS; Gilbert SC; Pollard AJ; Lambe T Nat Med 2021[Feb]; 27 (2): 270-278 PMID33335323show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective vaccines are urgently needed(1). Strong, Th1-skewed T cell responses can drive protective humoral and cell-mediated immune responses(2) and might reduce the potential for disease enhancement(3). Cytotoxic T cells clear virus-infected host cells and contribute to control of infection(4). Studies of patients infected with SARS-CoV-2 have suggested a protective role for both humoral and cell-mediated immune responses in recovery from COVID-19 (refs. (5,6)). ChAdOx1 nCoV-19 (AZD1222) is a candidate SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein. We recently reported preliminary safety and immunogenicity data from a phase 1/2 trial of the ChAdOx1 nCoV-19 vaccine (NCT04400838)(7) given as either a one- or two-dose regimen. The vaccine was tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. Here we describe, in detail, exploratory analyses of the immune responses in adults, aged 18-55 years, up to 8 weeks after vaccination with a single dose of ChAdOx1 nCoV-19 in this trial, demonstrating an induction of a Th1-biased response characterized by interferon-gamma and tumor necrosis factor-alpha cytokine secretion by CD4(+) T cells and antibody production predominantly of IgG1 and IgG3 subclasses. CD8(+) T cells, of monofunctional, polyfunctional and cytotoxic phenotypes, were also induced. Taken together, these results suggest a favorable immune profile induced by ChAdOx1 nCoV-19 vaccine, supporting the progression of this vaccine candidate to ongoing phase 2/3 trials to assess vaccine efficacy. |Adolescent[MESH] |Antibody Formation/*immunology[MESH] |CD4-Positive T-Lymphocytes/immunology[MESH] |CD8-Positive T-Lymphocytes/immunology[MESH] |COVID-19 Vaccines/*immunology[MESH] |COVID-19/immunology/virology[MESH] |ChAdOx1 nCoV-19[MESH] |Dose-Response Relationship, Immunologic[MESH] |Female[MESH] |Humans[MESH] |Immunity, Cellular[MESH] |Immunity, Humoral[MESH] |Immunoglobulin A/immunology[MESH] |Immunoglobulin M/immunology[MESH] |Interferon-gamma/metabolism[MESH] |Lymphocyte Activation/immunology[MESH] |Male[MESH] |Middle Aged[MESH] |Protein Subunits/immunology[MESH] |SARS-CoV-2/immunology[MESH] |Spike Glycoprotein, Coronavirus/immunology[MESH] |T-Lymphocytes/*immunology[MESH] |Vaccination[MESH]T cell and antibody responses induced by a single dose of ChAdOx1 nCoV(epmc).pdf DeepDyve Pubget Overpricing